EP1631311A4 - Anticorps humanises anti-ccr2 et leurs procedes d'utilisation - Google Patents

Anticorps humanises anti-ccr2 et leurs procedes d'utilisation

Info

Publication number
EP1631311A4
EP1631311A4 EP03819151A EP03819151A EP1631311A4 EP 1631311 A4 EP1631311 A4 EP 1631311A4 EP 03819151 A EP03819151 A EP 03819151A EP 03819151 A EP03819151 A EP 03819151A EP 1631311 A4 EP1631311 A4 EP 1631311A4
Authority
EP
European Patent Office
Prior art keywords
methods
humanized anti
ccr2 antibodies
ccr2
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP03819151A
Other languages
German (de)
English (en)
Other versions
EP1631311A2 (fr
Inventor
Theresa O'keefe
Paul Ponath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to EP09169287A priority Critical patent/EP2135619A1/fr
Publication of EP1631311A2 publication Critical patent/EP1631311A2/fr
Publication of EP1631311A4 publication Critical patent/EP1631311A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP03819151A 2003-12-10 2003-12-10 Anticorps humanises anti-ccr2 et leurs procedes d'utilisation Ceased EP1631311A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09169287A EP2135619A1 (fr) 2003-12-10 2003-12-10 Anticorps humanisés anti-CCR2 et leurs procédés d'utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/039599 WO2005060368A2 (fr) 2003-12-10 2003-12-10 Anticorps humanises anti-ccr2 et leurs procedes d'utilisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP09169287A Division EP2135619A1 (fr) 2003-12-10 2003-12-10 Anticorps humanisés anti-CCR2 et leurs procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP1631311A2 EP1631311A2 (fr) 2006-03-08
EP1631311A4 true EP1631311A4 (fr) 2007-04-11

Family

ID=34709648

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03819151A Ceased EP1631311A4 (fr) 2003-12-10 2003-12-10 Anticorps humanises anti-ccr2 et leurs procedes d'utilisation
EP09169287A Withdrawn EP2135619A1 (fr) 2003-12-10 2003-12-10 Anticorps humanisés anti-CCR2 et leurs procédés d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP09169287A Withdrawn EP2135619A1 (fr) 2003-12-10 2003-12-10 Anticorps humanisés anti-CCR2 et leurs procédés d'utilisation

Country Status (7)

Country Link
EP (2) EP1631311A4 (fr)
JP (1) JP2007521248A (fr)
AU (1) AU2003300896A1 (fr)
CA (1) CA2529694A1 (fr)
IL (1) IL172533A (fr)
MX (1) MXPA06000176A (fr)
WO (1) WO2005060368A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006015341A1 (de) * 2006-04-03 2007-10-04 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
WO2010021697A2 (fr) 2008-08-18 2010-02-25 Pfizer Inc. Anticorps anti-ccr2
EP2588498B1 (fr) * 2010-06-29 2018-07-11 Centre National de la Recherche Scientifique (CNRS) Anticorps dirigés contre llt-1 et ayant de nouvelles propriétés fonctionnelles
EP2864358B1 (fr) 2012-06-22 2019-08-07 Sorrento Therapeutics, Inc. Protéines de liaison à un antigène qui se lient à ccr2
PT3112462T (pt) * 2014-02-28 2019-02-08 Astellas Pharma Inc Novos anticorpos biespecíficos ligando a tlr2 humano e tlr4 humano
WO2016081801A1 (fr) * 2014-11-21 2016-05-26 Millennium Pharmaceuticals, Inc. Utilisation d'un antagoniste anti-ccr2 dans le traitement d'une maladie infectieuse
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058679A1 (fr) * 1998-05-09 1999-11-18 Glaxo Group Limited Anticorps diriges contre la cd23, derives de ces derniers et utilisations therapeutiques
WO2001057226A1 (fr) * 2000-02-03 2001-08-09 Millennium Pharmaceuticals, Inc. Anticorps humanises anti-ccr2 et procedes d'utilisation de ces anticorps
WO2001070266A2 (fr) * 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Methode d'inhibition de la stenose et de la restenose
WO2002062383A2 (fr) * 2001-02-08 2002-08-15 Smithkline Beecham P.L.C. Nouvelle methode de traitement
US20020150576A1 (en) * 1998-07-23 2002-10-17 Larosa Gregory J. Humanized anti-CCR2 antibodies and methods of use therefor
WO2002102853A2 (fr) * 2001-06-14 2002-12-27 Isis Innovation Limited Anticorps trx1 et utilisations associees

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4172124A (en) 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
US5292668A (en) 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
WO1989007142A1 (fr) 1988-02-05 1989-08-10 Morrison Sherie L Anticorps a region constante a modification de domaine
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
CA2006408A1 (fr) 1988-12-27 1990-06-27 Susumu Iwasa Anticorps monoclaux bispecifiques, production et utilisation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5284746A (en) 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
TW212184B (fr) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5182366A (en) 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5948647A (en) 1990-10-29 1999-09-07 Chiron Corporation Nucleic acids encoding antigen-binding sites specific for cancer antigens
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2119930C (fr) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production d'anticorps chimeres - demarche combinatoire
US5508384A (en) 1992-09-10 1996-04-16 New York University Polypeptide derived from a popamine receptor, and compositions and methods thereof
JP3553937B2 (ja) 1992-12-01 2004-08-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 配位触媒システム
CA2115811A1 (fr) 1993-02-17 1994-08-18 Claus Krebber Methode de selection in vivo de proteines fixatrices de ligands
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
WO1994026087A2 (fr) 1993-05-14 1994-11-24 Connor Kim C O Production de proteines de recombinaison, culture de cellules d'insectes et procede s'y rapportant
CA2163345A1 (fr) 1993-06-16 1994-12-22 Susan Adrienne Morgan Anticorps
EP0740701B1 (fr) 1994-01-13 2006-12-06 The Regents of the University of California Recepteurs de proteine chimioattractive monocytaire de mammifere
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US5856571A (en) 1995-06-07 1999-01-05 Cellpro, Incorporated Semicarbazide-containing linker compounds for formation of stably-linked conjugates and methods related thereto
WO1996040662A2 (fr) 1995-06-07 1996-12-19 Cellpro, Incorporated Composes de liaison contenant un groupe aminooxy et leur utilisation pour la formation de conjugues
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US20020042370A1 (en) * 2000-04-14 2002-04-11 Millennium Pharmaceuticals, Inc. Method of treating graft rejection using inhibitors of CCR2 function

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058679A1 (fr) * 1998-05-09 1999-11-18 Glaxo Group Limited Anticorps diriges contre la cd23, derives de ces derniers et utilisations therapeutiques
US20020150576A1 (en) * 1998-07-23 2002-10-17 Larosa Gregory J. Humanized anti-CCR2 antibodies and methods of use therefor
WO2001057226A1 (fr) * 2000-02-03 2001-08-09 Millennium Pharmaceuticals, Inc. Anticorps humanises anti-ccr2 et procedes d'utilisation de ces anticorps
WO2001070266A2 (fr) * 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Methode d'inhibition de la stenose et de la restenose
WO2002062383A2 (fr) * 2001-02-08 2002-08-15 Smithkline Beecham P.L.C. Nouvelle methode de traitement
WO2002102853A2 (fr) * 2001-06-14 2002-12-27 Isis Innovation Limited Anticorps trx1 et utilisations associees

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALBINI ADRIANA: "HIV-1 Tat protein mimicry of chemokines", PROC. NATL. ACAD. SCI., vol. 95, October 1998 (1998-10-01), USA, pages 13153 - 13158, XP002146039, DOI: 10.1073/pnas.95.22.13153 *
COMBADIERE: "Monocyte Chemoattractant Protein-3 is a functional ligand for CC Chemokine Receptors 1 and 2B", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 50, 1998, USA, pages 29671 - 29675 *
GODISKA: "Monocte chemotactic protein-4: tissue-specific expression and signaling trhough CC chemokine receptor-2", J. LEUKOC. BIOL., vol. 61, March 1997 (1997-03-01), pages 353 - 360 *
GONG: "Monocyte chemotactic protein-2 (MCP-2) uses CCR+ and CCR2B as its functional receptors", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 18, 2 May 1997 (1997-05-02), usa, pages 11682 - 11695 *
SARAFI M.: "Murine Monocyte chemoattractant proetein (MCP)-5 a novel CC chemokine that is a structural and functional homologue of human MCP-1", J. EXP. MED., vol. 185, no. 1, 6 January 1997 (1997-01-06), USA, pages 99 - 109, XP055035882, DOI: 10.1084/jem.185.1.99 *

Also Published As

Publication number Publication date
IL172533A (en) 2012-02-29
MXPA06000176A (es) 2006-06-27
EP1631311A2 (fr) 2006-03-08
AU2003300896A1 (en) 2005-07-14
JP2007521248A (ja) 2007-08-02
WO2005060368A2 (fr) 2005-07-07
CA2529694A1 (fr) 2005-07-07
WO2005060368A3 (fr) 2005-12-22
IL172533A0 (en) 2006-04-10
EP2135619A1 (fr) 2009-12-23

Similar Documents

Publication Publication Date Title
HK1219487A1 (zh) 特異抗體及使用它們的方法
IL179102A (en) Human-specific fcγriib antibodies and methods for their use
IL178593A (en) Specific antibodies of fcγriib and methods for their use
IL172689A0 (en) Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
HK1099935A1 (en) Anti-cd3 antibodies and methods of use thereof -cd3
IL157142A0 (en) Modified antibodies and methods of use
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
TWI350291B (en) Crystal of anti-egfr antibodies
EP1833849A4 (fr) Anticorps specifiques de fc gamma riib et leurs procedes d'utilisation
EP1841452B8 (fr) Anticorps a domaine unique contre le tnfr1 et procedes et leur utilisations
ZA200507067B (en) Antibodies against human IL-21 receptor and uses therefor
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
EP1482984A4 (fr) Anticorps de substitution et leurs procedes de preparation et d'utilisation
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
ZA200506790B (en) Arylvinylazacycloalkane compounds and method of preparation and use thereof
EP1689346A4 (fr) Anticorps monoclonaux agonistiques epha2 et procedes d'utilisation correspondants
AU2002340167A8 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2003277259A8 (en) Immunoassay and method of use
EP1591062A4 (fr) Dispositif de magnetoencephalographie et son procede d'utilisation
IL172533A0 (en) Humanized anti-ccr2 antibodies and methods of use
EP1699485A4 (fr) Anticorps anti-hydroxylase et utilisations
EP1497654A4 (fr) Vaccins d'immunoglobuline e et leurs procedes d'utilisation
IL172510A0 (en) Antibodies and uses thereof
EP1633749A4 (fr) Composes de deazaflavine et leurs methodes d'utilisation
EP1589033A4 (fr) Anticorps et utilisation de ce dernier

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051214

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1082205

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070312

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20070306BHEP

Ipc: A61K 39/395 20060101AFI20051228BHEP

17Q First examination report despatched

Effective date: 20070803

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20091102

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1082205

Country of ref document: HK